OncoMatch/Clinical Trials/NCT07349069
A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With High-Risk Early Breast Cancer
Is NCT07349069 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including HRS-8080 Tablets and Letrozole tablets for breast cancer.
Treatment: HRS-8080 Tablets · Letrozole tablets · Tamoxifen Citrate Tablets — The study is being conducted to evaluate the efficacy and safety of HRS-8080 in patients with high-risk early breast cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Disease stage
Required: Stage II, III
Excluded: Stage IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: endocrine therapy — adjuvant
having received at least 2 years, but no more than 5 years, of adjuvant endocrine therapy
Lab requirements
Blood counts
Adequate organ and bone marrow function
Kidney function
Adequate organ and bone marrow function
Liver function
Adequate organ and bone marrow function
Cardiac function
Poor cardiac function [excluded]
Adequate organ and bone marrow function; Poor cardiac function [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify